

For Immediate Release



ASX Announcement

29 July, 2026
Melbourne, Australia

CSL to launch clinical trials to evaluate enhanced plasma manufacturing

CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it will undertake clinical trial work to confirm the efficacy and safety of immunoglobulin manufactured using its next generation Horizon 2 process. Horizon 2 is a patented, yield-enhancing technology that enables significantly greater production of immunoglobulin from the same base amount of plasma.

Following its engagements with the U.S. Food & Drug Administration (FDA) and European Medicines Agency (EMA), CSL will obtain clinical evidence to support and finalise the regulatory approval processes for Horizon 2.

CSL's advanced manufacturing processes are among several initiatives it continues to progress as part of an overall focus on operational efficiencies.

CSL expects clinical activities to commence in mid-2027, using material manufactured at CSL's Broadmeadows facility. This will allow the clinical trial work to be undertaken in parallel with construction of the previously announced expansion of CSL's Kankakee, Illinois manufacturing facility.

Further information on the duration of the clinical trial work and the impact on the regulatory approval process for Horizon 2 will be provided to investors when available.

Authorised for lodgement by:

Fiona Mead
Company Secretary



Investor Relations

Michelle Rees
Investor Relations
CSL Limited
P: +61 410 600 745
E: michelle.rees@csl.com.au



Media Relations

Brett Foley
Media
CSL Limited
P: +61 461 464 708
E: media@csl.com.au

CSL Limited | ABN 99 051 588 348 | 655 Elizabeth Street, Melbourne VIC 3000